Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective
- PMID: 15691232
- PMCID: PMC7169139
- DOI: 10.1111/j.1440-1843.2005.00692.x
Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective
Abstract
Chronic obstructive pulmonary disease (COPD) is a major public health problem and its prevalence and mortality are increasing throughout the world, including the Asia-Pacific region. To arrest these worldwide trends, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Expert Panel's global strategy for the diagnosis, management, and prevention of COPD was published in 2001. Based on recently published clinical trials, the GOLD statement was updated in 2003. The Asia-Pacific COPD Roundtable Group, a taskforce of expert respirologists from the Asia-Pacific region, has recently formulated a consensus statement on implementation of the GOLD strategy for COPD in the Asia-Pacific region. The key issues identified by the COPD Roundtable Group for comment are: (i) where there is no access to spirometry, diagnosis of COPD could be suspected on the basis of history, symptoms and physical signs; (ii) inhaled bronchodilators are the preferred regular treatment for COPD in the region, but oral bronchodilators may be considered if the cost of inhaled bronchodilators is a barrier to treatment; (iii) the use of a Metered Dose Inhaler with spacer in place of a nebulizer is recommended in the treatment of acute airflow obstruction in patients with COPD; (iv) influenza vaccination is recommended for all patients with COPD in communities where there is a high likelihood of Severe Acute Respiratory Syndrome; and (v) simplified pulmonary rehabilitation programmes should be established in areas where comprehensive programmes are unavailable. Physical exercise training and education on smoking cessation should be core elements of any rehabilitation program. In summary, the COPD Roundtable Group supports implementation of the GOLD strategy for the diagnosis, management and prevention of COPD in the Asia-Pacific region, subject to the additions and modifications to the guidelines suggested above.
Conflict of interest statement
Unconditional educational grants from Boehringer Ingelheim and Pfizer covered the costs of the Group's meetings and the writing of the consensus statement. The deliberations of the Group were free of any influence from the funding companies. Members of The Asia Pacific COPD Roundtable Group have acted as consultants for several pharmaceutical companies, including Boehringer Ingelheim and Pfizer, and have spoken at meetings sponsored by pharmaceutical companies, including Boehringer Ingelheim and Pfizer.
Similar articles
-
Guideline for the management of chronic obstructive pulmonary disease--2011 update.S Afr Med J. 2011 Jan;101(1 Pt 2):63-73. S Afr Med J. 2011. PMID: 21526617
-
COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.Med J Aust. 2017 Nov 20;207(10):436-442. doi: 10.5694/mja17.00686. Med J Aust. 2017. PMID: 29129177
-
Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.S Afr Med J. 2004 Jul;94(7 Pt 2):559-75. S Afr Med J. 2004. PMID: 15283307
-
The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?Clin Respir J. 2012 Oct;6(4):208-14. doi: 10.1111/crj.12002. Clin Respir J. 2012. PMID: 22906068 Review.
-
Contemporary issues in the care of patients with chronic obstructive pulmonary disease.J Manag Care Pharm. 2005 Jun;11(5 Suppl A):S2-13; quiz S14-6. doi: 10.18553/jmcp.2005.11.s5-a.1. J Manag Care Pharm. 2005. PMID: 15934804 Free PMC article. Review.
Cited by
-
Establishing normal reference values in quantitative computed tomography of emphysema.J Thorac Imaging. 2013 Sep;28(5):280-3. doi: 10.1097/RTI.0b013e3182a0d805. J Thorac Imaging. 2013. PMID: 23966092 Free PMC article. Review.
-
Effect of continuous nursing care based on the IKAP theory on the quality of life of patients with chronic obstructive pulmonary disease: A randomized controlled study.Medicine (Baltimore). 2020 Mar;99(11):e19543. doi: 10.1097/MD.0000000000019543. Medicine (Baltimore). 2020. PMID: 32176107 Free PMC article. Clinical Trial.
-
Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids.Osteoporos Int. 2013 Jun;24(6):1891-7. doi: 10.1007/s00198-012-2220-6. Epub 2012 Nov 14. Osteoporos Int. 2013. PMID: 23152095
-
Extracellular matrix promotes proliferation, migration and adhesion of airway smooth muscle cells in a rat model of chronic obstructive pulmonary disease via upregulation of the PI3K/AKT signaling pathway.Mol Med Rep. 2018 Sep;18(3):3143-3152. doi: 10.3892/mmr.2018.9320. Epub 2018 Jul 25. Mol Med Rep. 2018. PMID: 30066869 Free PMC article.
-
The precarious balance between 'supply' and 'demand' for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2008;3(3):393-6. doi: 10.2147/copd.s3568. Int J Chron Obstruct Pulmon Dis. 2008. PMID: 18990966 Free PMC article. Review.
References
-
- Murray CJL, Lopez AD. Evidence‐based health policy—lessons from the global burden of disease study. Science 1996; 274: 740–3. - PubMed
-
- Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Cambridge, MA, 1996.
-
- Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436–42. - PubMed
-
- Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options. Pharmacoeconomics 2001; 19: 245–54. - PubMed
-
- Barnes PJ. Chronic obstructive pulmonary disease: new opportunities for drug development. Trends Pharmacol. Sci. 1998; 19: 415–23. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical